Correction: A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01).

Oncotarget

Published: August 2017

The article in question has been corrected to address inaccuracies or errors previously published in the original work.
The DOI (Digital Object Identifier) is a unique identifier that helps locate the specific article in academic and research databases.
Corrections like this ensure that the scientific community has access to accurate and reliable information for research and study purposes.

[This corrects the article DOI: 10.18632/oncotarget.13056.].

Download full-text PDF	Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5589698	PMC
http://dx.doi.org/10.18632/oncotarget.20268	DOI Listing

Publication Analysis

correction randomized

randomized phase

phase study

study gefitinib

gefitinib versus

versus nimotuzumab

nimotuzumab gefitinib

gefitinib platinum-based

platinum-based chemotherapy

chemotherapy advanced

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!